Enliven Therapeutics ELVN
$46.53 +$0.12 (+0.26%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $46.53 0.00%
Open$46.05
Prev close$46.41
Day range$45.64 – $47.83
Volume933.6K
Market cap$3.42B
P/E (TTM)–
Dividend yield–
ELVN Stock News
Headlines matching Enliven Therapeutics or the ELVN ticker, most recent first.
- LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 Positive
- LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
- A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
- Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $73 Positive
- William Blair Initiates Enliven Therapeutics(ELVN.US) With Buy Rating
- Barclays Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $78
- Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
- H.C. Wainwright Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $64 Positive
- Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $67 Positive
- Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $80 Positive
- Stifel Initiates Enliven Therapeutics(ELVN.US) With Buy Rating, Announces Target Price $60
- Goldman Sachs Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $59
- JonesTrading Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70 Positive
- Mizuho Securities Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $62 Positive
- Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $60
No comments yet — be the first to weigh in on ELVN.
Sign in to join the discussion.